Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Bristol’s Opdivo Delay May Help It Beat Out BRAF Inhibitors

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm announces three-month user fee extension for first-line melanoma claim for Opdivo, but the firm’s statement suggests a silver lining.

Advertisement

Related Content

PD-1 Progress May Shorten The Life Of Other Drugs
Opdivo/Yervoy Data Show Role For Checkpoint Combos; ASCO Debates Biomarkers

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register